Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

News from DMCCB - Targeted Protein Degradation.

Jaeschke G.

Chimia (Aarau). 2018 Dec 19;72(12):903-904. doi: 10.2533/chimia.2018.903. No abstract available.

PMID:
30648961
2.

mGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex.

Kelly E, Schaeffer SM, Dhamne SC, Lipton JO, Lindemann L, Honer M, Jaeschke G, Super CE, Lammers SH, Modi ME, Silverman JL, Dreier JR, Kwiatkowski DJ, Rotenberg A, Sahin M.

Neuropsychopharmacology. 2018 May;43(6):1457-1465. doi: 10.1038/npp.2017.295. Epub 2017 Dec 5.

3.

Results and evaluation of a first-in-human study of RG7342, an mGlu5 positive allosteric modulator, utilizing Bayesian adaptive methods.

Sturm S, Delporte ML, Hadi S, Schobel S, Lindemann L, Weikert R, Jaeschke G, Derks M, Palermo G.

Br J Clin Pharmacol. 2018 Mar;84(3):445-455. doi: 10.1111/bcp.13466. Epub 2017 Dec 18.

4.

Blocking metabotropic glutamate receptor subtype 5 relieves maladaptive chronic stress consequences.

Peterlik D, Stangl C, Bauer A, Bludau A, Keller J, Grabski D, Killian T, Schmidt D, Zajicek F, Jaeschke G, Lindemann L, Reber SO, Flor PJ, Uschold-Schmidt N.

Brain Behav Immun. 2017 Jan;59:79-92. doi: 10.1016/j.bbi.2016.08.007. Epub 2016 Aug 11.

PMID:
27524668
5.

Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression.

Lindemann L, Porter RH, Scharf SH, Kuennecke B, Bruns A, von Kienlin M, Harrison AC, Paehler A, Funk C, Gloge A, Schneider M, Parrott NJ, Polonchuk L, Niederhauser U, Morairty SR, Kilduff TS, Vieira E, Kolczewski S, Wichmann J, Hartung T, Honer M, Borroni E, Moreau JL, Prinssen E, Spooren W, Wettstein JG, Jaeschke G.

J Pharmacol Exp Ther. 2015 Apr;353(1):213-33. doi: 10.1124/jpet.114.222463. Epub 2015 Feb 9.

PMID:
25665805
6.

Contribution of mGluR5 to pathophysiology in a mouse model of human chromosome 16p11.2 microdeletion.

Tian D, Stoppel LJ, Heynen AJ, Lindemann L, Jaeschke G, Mills AA, Bear MF.

Nat Neurosci. 2015 Feb;18(2):182-4. doi: 10.1038/nn.3911. Epub 2015 Jan 12.

7.

Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases.

Jaeschke G, Kolczewski S, Spooren W, Vieira E, Bitter-Stoll N, Boissin P, Borroni E, Büttelmann B, Ceccarelli S, Clemann N, David B, Funk C, Guba W, Harrison A, Hartung T, Honer M, Huwyler J, Kuratli M, Niederhauser U, Pähler A, Peters JU, Petersen A, Prinssen E, Ricci A, Rueher D, Rueher M, Schneider M, Spurr P, Stoll T, Tännler D, Wichmann J, Porter RH, Wettstein JG, Lindemann L.

J Med Chem. 2015 Feb 12;58(3):1358-71. doi: 10.1021/jm501642c. Epub 2015 Feb 2.

PMID:
25565255
8.

Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.

Scharf SH, Jaeschke G, Wettstein JG, Lindemann L.

Curr Opin Pharmacol. 2015 Feb;20:124-34. doi: 10.1016/j.coph.2014.11.004. Epub 2014 Dec 2. Review.

PMID:
25488569
9.

Yeast synthetic biology platform generates novel chemical structures as scaffolds for drug discovery.

Klein J, Heal JR, Hamilton WD, Boussemghoune T, Tange TØ, Delegrange F, Jaeschke G, Hatsch A, Heim J.

ACS Synth Biol. 2014 May 16;3(5):314-23. doi: 10.1021/sb400177x. Epub 2014 Jan 30.

10.

Chronic metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity and improves cognitive performance in fragile X mice.

Michalon A, Bruns A, Risterucci C, Honer M, Ballard TM, Ozmen L, Jaeschke G, Wettstein JG, von Kienlin M, Künnecke B, Lindemann L.

Biol Psychiatry. 2014 Feb 1;75(3):189-97. doi: 10.1016/j.biopsych.2013.05.038. Epub 2013 Jul 30.

PMID:
23910948
11.

Differential effects of diazepam and MPEP on habituation and neuro-behavioural processes in inbred mice.

Salomons AR, Pinzon NE, Boleij H, Kirchhoff S, Arndt SS, Nordquist RE, Lindemann L, Jaeschke G, Spooren W, Ohl F.

Behav Brain Funct. 2012 Jun 11;8:30. doi: 10.1186/1744-9081-8-30.

12.

Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.

Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, Jaeschke G, Bear MF, Lindemann L.

Neuron. 2012 Apr 12;74(1):49-56. doi: 10.1016/j.neuron.2012.03.009.

13.

CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor.

Lindemann L, Jaeschke G, Michalon A, Vieira E, Honer M, Spooren W, Porter R, Hartung T, Kolczewski S, Büttelmann B, Flament C, Diener C, Fischer C, Gatti S, Prinssen EP, Parrott N, Hoffmann G, Wettstein JG.

J Pharmacol Exp Ther. 2011 Nov;339(2):474-86. doi: 10.1124/jpet.111.185660. Epub 2011 Aug 17.

PMID:
21849627
14.

Enantioselective total synthesis of callipeltoside A: two approaches to the macrolactone fragment.

Evans DA, Burch JD, Hu E, Jaeschke G.

Tetrahedron. 2008 May 19;64(21):4674-4699.

15.

Metabolite identification via LC-SPE-NMR-MS of the in vitro biooxidation products of a lead mGlu5 allosteric antagonist and impact on the improvement of metabolic stability in the series.

Ceccarelli SM, Schlotterbeck G, Boissin P, Binder M, Buettelmann B, Hanlon S, Jaeschke G, Kolczewski S, Kupfer E, Peters JU, Porter RH, Prinssen EP, Rueher M, Ruf I, Spooren W, Stämpfli A, Vieira E.

ChemMedChem. 2008 Jan;3(1):136-44.

PMID:
17994660
16.

Stress-induced hyperthermia: effects of acute and repeated dosing of MPEP.

Nordquist RE, Durkin S, Jaeschke G, Spooren W.

Eur J Pharmacol. 2007 Jul 30;568(1-3):199-202. Epub 2007 Apr 30.

PMID:
17537432
17.

Predicting and tuning physicochemical properties in lead optimization: amine basicities.

Morgenthaler M, Schweizer E, Hoffmann-Röder A, Benini F, Martin RE, Jaeschke G, Wagner B, Fischer H, Bendels S, Zimmerli D, Schneider J, Diederich F, Kansy M, Müller K.

ChemMedChem. 2007 Aug;2(8):1100-15. Review.

PMID:
17530727
18.

Synthesis and biological evaluation of fenobam analogs as mGlu5 receptor antagonists.

Jaeschke G, Porter R, Büttelmann B, Ceccarelli SM, Guba W, Kuhn B, Kolczewski S, Huwyler J, Mutel V, Peters JU, Ballard T, Prinssen E, Vieira E, Wichmann J, Spooren W.

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1307-11. Epub 2006 Dec 15.

PMID:
17196387
19.

Rational design, synthesis, and structure-activity relationship of benzoxazolones: new potent mglu5 receptor antagonists based on the fenobam structure.

Ceccarelli SM, Jaeschke G, Buettelmann B, Huwyler J, Kolczewski S, Peters JU, Prinssen E, Porter R, Spooren W, Vieira E.

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1302-6. Epub 2006 Dec 15.

PMID:
17189691
20.

Comparison of the binding pockets of two chemically unrelated allosteric antagonists of the mGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP.

Malherbe P, Kratochwil N, Mühlemann A, Zenner MT, Fischer C, Stahl M, Gerber PR, Jaeschke G, Porter RH.

J Neurochem. 2006 Jul;98(2):601-15.

21.

Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonists.

Büttelmann B, Peters JU, Ceccarelli S, Kolczewski S, Vieira E, Prinssen EP, Spooren W, Schuler F, Huwyler J, Porter RH, Jaeschke G.

Bioorg Med Chem Lett. 2006 Apr 1;16(7):1892-7. Epub 2006 Jan 24.

PMID:
16439120
22.

Determination of key amino acids implicated in the actions of allosteric modulation by 3,3'-difluorobenzaldazine on rat mGlu5 receptors.

Mühlemann A, Ward NA, Kratochwil N, Diener C, Fischer C, Stucki A, Jaeschke G, Malherbe P, Porter RH.

Eur J Pharmacol. 2006 Jan 4;529(1-3):95-104. Epub 2005 Dec 13.

PMID:
16352303
23.

Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity.

Porter RH, Jaeschke G, Spooren W, Ballard TM, Büttelmann B, Kolczewski S, Peters JU, Prinssen E, Wichmann J, Vieira E, Mühlemann A, Gatti S, Mutel V, Malherbe P.

J Pharmacol Exp Ther. 2005 Nov;315(2):711-21. Epub 2005 Jul 22.

PMID:
16040814
24.

Enantioselective total synthesis of callipeltoside A.

Evans DA, Hu E, Burch JD, Jaeschke G.

J Am Chem Soc. 2002 May 22;124(20):5654-5.

PMID:
12010035
25.

Discovery of (R)-1-[2-hydroxy-3-(4-hydroxy-phenyl)-propyl]-4-(4-methyl-benzyl)-piperidin-4-ol: a novel NR1/2B subtype selective NMDA receptor antagonist.

Pinard E, Alanine A, Bourson A, Büttelmann B, Gill R, Heitz M, Jaeschke G, Mutel V, Trube G, Wyler R.

Bioorg Med Chem Lett. 2001 Aug 20;11(16):2173-6.

PMID:
11514163
26.

Identification and verification of the anabolic steroid boldenone in equine blood and urine by HPLC/ELISA.

Hagedorn HW, Schulz R, Jaeschke G.

Biomed Chromatogr. 1994 Mar-Apr;8(2):63-8.

PMID:
8044023
27.

[Equine influenza outbreaks with viral antigenic drift in Berlin 1988-1991].

Jaeschke G, Lange W.

Berl Munch Tierarztl Wochenschr. 1993 Apr;106(4):119-23. German.

PMID:
8387774
28.

[Clinical chemistry in leukosis of horses (review)].

Jaeschke G, Rudolph R.

Berl Munch Tierarztl Wochenschr. 1992 Apr 1;105(4):114-22. Review. German.

PMID:
1596267
29.

[Hematology and cytodiagnosis of leukosis of the horse (review)].

Jaeschke G, Rudolph R.

Berl Munch Tierarztl Wochenschr. 1991 Nov 1;104(11):369-74. Review. German.

PMID:
1772391
30.

[Clinical diagnostic keys and special manifestations in equine leukosis].

Jaeschke G, Rudolph R.

Berl Munch Tierarztl Wochenschr. 1991 Sep 1;104(9):303-7. Review. German.

PMID:
1953630
31.

[Training-induced changes of reference vectors in the QRS complex of the EKG of young trotting horses].

Grauerholz H, Jaeschke G.

Berl Munch Tierarztl Wochenschr. 1990 Oct 1;103(10):329-35. German.

PMID:
2248611
32.

[The construction of the main and reference vectors from the limb circuits in the ECG of the horse].

Grauerholz H, Jaeschke G.

Berl Munch Tierarztl Wochenschr. 1988 Nov 1;101(11):376-8. German. No abstract available.

PMID:
3196282
33.

[The diagnosis of morbus maculosus in horses].

Jaeschke G, Wintzer HJ.

Tierarztl Prax. 1988;16(4):385-94. Review. German.

PMID:
3065980
34.

[Influenza epidemic in horses in West Berlin 1983-1985. 2. Virological and serological findings].

Lange W, Jaeschke G.

Dtsch Tierarztl Wochenschr. 1987 Mar 9;94(3):157-60. German. No abstract available.

PMID:
3032558
35.

[Influenza epidemic in horses in West Berlin 1983-1985. 1. Clinical and hematological findings].

Jaeschke G, Lange W.

Dtsch Tierarztl Wochenschr. 1987 Mar 9;94(3):153-5. German. No abstract available.

PMID:
3032557
36.

[Problems in measuring and evaluating QRS duration in the ECG of the horse].

Grauerholz H, Jaeschke G.

Berl Munch Tierarztl Wochenschr. 1986 Nov 1;99(11):365-9. German. No abstract available.

PMID:
3814064
37.

[Horse leukosis. 4. Bibliography].

Jaeschke G, Rudolph R.

Berl Munch Tierarztl Wochenschr. 1986 Mar 1;99(3):88-95. German. No abstract available.

PMID:
3516136
38.

[Leukosis in the horse. 3. Hematology and clinical chemistry].

Jaeschke G, Rudolph R.

Berl Munch Tierarztl Wochenschr. 1986 Jan 1;99(1):4-14. German. No abstract available.

PMID:
3954722
39.

[Equine leukosis. 2. Clinical aspects and pathology in our own patients].

Jaeschke G, Rudolph R.

Berl Munch Tierarztl Wochenschr. 1985 Jun 1;98(6):202-8. German. No abstract available.

PMID:
4026794
40.

[Equine leukosis. 1. Nomenclature, clinical aspects and pathology (review)].

Jaeschke G, Rudolph R.

Berl Munch Tierarztl Wochenschr. 1985 Mar 1;98(3):88-94. Review. German. No abstract available.

PMID:
3888190
41.

Pharmacokinetics of ascorbic acid in horses.

Löscher W, Jaeschke G, Keller H.

Equine Vet J. 1984 Jan;16(1):59-65.

PMID:
6714208
42.

[Doping of performance horses with psychotropic drugs].

Jaeschke G.

Dtsch Tierarztl Wochenschr. 1983 Feb 7;90(2):59-64. Review. German. No abstract available.

PMID:
6131808
43.

[Causal treatment of arthrosis deformans in horses with glucosaminsulfate].

Jaeschke G, Steinbach W.

Dtsch Tierarztl Wochenschr. 1982 Jul 6;89(7):288-93. German. No abstract available.

PMID:
6751775
44.

[Ascorbic acid status of horses. 4. Behavior of serum levels following intravenous administration].

Jaeschke G, Keller H.

Berl Munch Tierarztl Wochenschr. 1982 Feb 15;95(4):71-6. German. No abstract available.

PMID:
7082277
45.

[The ascorbic acid status of the horse. 3. Behavior of serum levels after oral, subcutaneous and intramuscular administration].

Jaeschke G, Keller H.

Berl Munch Tierarztl Wochenschr. 1982 Jan 1;95(1):1-5. German. No abstract available.

PMID:
7059337
46.

[Clinical chemistry examinations of bone and muscle metabolism under stress in the Göttingen miniature pig--an experimental study].

Laiblin C, Jaeschke G.

Berl Munch Tierarztl Wochenschr. 1979 Mar 15;92(6):124-8. German. No abstract available.

PMID:
435236
47.

[The halothane-oxygen anesthesia in the horse following premedication with atropine combelen and chloral hydrate].

Wintzer HJ, Keller H, Müller R, Jaeschke G.

Berl Munch Tierarztl Wochenschr. 1979 Mar 1;92(5):81-4. German. No abstract available.

PMID:
420694
48.

[Ascorbic acid status of the horse. 2. Clinical aspects and deficiency conditions].

Jaeschke G, Keller H.

Berl Munch Tierarztl Wochenschr. 1978 Oct 1;91(19):375-9. German. No abstract available.

PMID:
697721
49.

[The ascorbic-acid status of the horse. 1. Methods and normal values].

Jaeschke G, Keller H.

Berl Munch Tierarztl Wochenschr. 1978 Jul 15;91(14):279-86. German. No abstract available.

PMID:
678289
50.

[Routine determination of free hydroxyproline in horse serum. Methods and normal values].

Jaeschke G.

Zentralbl Veterinarmed A. 1975 Feb;22(2):89-101. German. No abstract available.

PMID:
806194

Supplemental Content

Loading ...
Support Center